(Q43031055)

12 November 2017

title

Efficacy of high-dose interferon in combination with ribavirin in patients with chronic hepatitis C resistant to interferon alone. (English)

1 reference

12 November 2017

1 reference

1 reference

A D Min

1

1 reference

12 November 2017

J L Jones

2

1 reference

12 November 2017

S Esposito

3

1 reference

12 November 2017

E Lebovics

4

1 reference

12 November 2017

I M Jacobson

5

1 reference

12 November 2017

F M Klion

6

1 reference

12 November 2017

I S Goldman

7

1 reference

12 November 2017

J M Geders

8

1 reference

12 November 2017

H Tobias

9

1 reference

12 November 2017

C Bodian

10

1 reference

12 November 2017

H C Bodenheimer

11

1 reference

12 November 2017

language of work or name

English

0 references

publication date

1 April 2001

1 reference

The American Journal of Gastroenterology

12 November 2017

published in

1 reference

12 November 2017

volume

96

1 reference

12 November 2017

issue

4

1 reference

12 November 2017

page(s)

1143-1149

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

12 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

Ribavirin treatment for chronic hepatitis C

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

Hepatic stellate (ITO) cells: expanding roles for a liver-specific pericyte

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

Treatment with interferon-alpha2a alone or interferon-alpha2a plus ribavirin in patients with chronic hepatitis C previously treated with interferon-alpha2a. CONSTRUCT Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

Sequential versus concomitant administration of ribavirin and interferon alfa-n3 in patients with chronic hepatitis C not responding to interferon alone: results of a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

Interferon-alpha-2B and ribavirin in combination for chronic hepatitis C patients not responding to interferon-alpha alone: an Italian multicenter, randomized, controlled, clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

Discrepancy between biochemical and virological responses to interferon-alpha in chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

Prospective study of plasma fibronectin in fulminant hepatitis: association with infection and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

Rising incidence of hepatocellular carcinoma in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1572-0241.2001.03692.X

10.1111/J.1572-0241.2001.03692.X

21 January 2018

Identifiers

DOI

1 reference

12 November 2017

1 reference